MetaVia presented three Sunday June 7 posters at ADA 2026. The Phase 1 higher-dose cohort of DA-1726, the once-weekly dual GLP-1/glucagon oxyntomodulin analog, builds on the prior 32 mg multiple-ascending-dose readout that showed strong effects on weight, glucose, and waist. The GPR119 agonist vanoglipel was presented in two combinations: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit.
MetaVia's three June 7 posters at ADA cover the higher-dose Part 3 cohort of its once-weekly dual GLP-1/glucagon agonist DA-1726, which previously cleared a 32 mg dose with strong weight, glucose, and waist effects in the multiple-ascending-dose study, and two combinations of its GPR119 agonist vanoglipel: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit. The company is small-cap but its readouts add depth to both the dual-agonist and GPR119 threads.
MetaVia confirmed Monday May 18 that three late-breaking abstracts have been accepted at the ADA 2026 Scientific Sessions (June 5-8 New Orleans). DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1R/GCGR dual agonist for obesity and MASH; Phase 1 Part 3 higher-dose titration results will be presented, with full Phase 1 trial data expected in Q4 2026. Vanoglipel (DA-1241) is a first-in-class GPR119 agonist that promotes endogenous release of GLP-1, GIP, and PYY from the gut; the ADA poster covers synergistic preclinical effects in combination with resmetirom (Madrigal's MASH therapy) and with metformin for type 2 diabetes. The three-poster slate positions MetaVia as one of several mid-cap obesity-pipeline names with clinical data inflections clustered into the ADA + ASCO + EASD 2026 calendar.